Updated 2026-08-25 · NCT07785934See eligibility →
Sponsor
Clinical trials sponsored by The United Bio-Technology (Hengqin) Co., Ltd.
Active studies whose public registry record names The United Bio-Technology (Hengqin) Co., Ltd. as lead sponsor.
6active studies
2recruiting now
1countries represented
1largest site network
Current studies
Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.
Recruiting nowPhase 2
UBT251 Injection Phase II Clinical Study (CKD)
Updated 2025-11-25 · NCT07134335See eligibility →
Opening soonPhase 3
UBT251 Injection Phase Ⅲ Study (OSA-PAP)
Updated 2026-09-08 · NCT07806851See eligibility →
Opening soonPhase 3
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
Updated 2026-08-25 · NCT07767942See eligibility →
Updated 2026-06-17 · NCT07653477See eligibility →
Opening soonPhase 3
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
Updated 2026-06-15 · NCT07648225See eligibility →
Related sponsors
Novo Nordisk A/S71Eli Lilly and Company67University of Colorado, Denver36Cairo University31Mayo Clinic29Norwegian University of Science and Technology25
How current is this page?
The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.
Does appearing here mean I qualify?
No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.